Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Zhan Wang, Bao-Dong Qin, Chen-Yang Ye, Miao-Miao Wang, Ling-Yan Yuan, Wei-Ping Dai, Li Sun, Ke Liu, Wen-Xing Qin, Xiao-Dong Jiao, Xing-Nan Li, Yuan-Sheng Zang
Summary: This study evaluated the safety and efficacy of a new protocol using vemurafenib and cetuximab combined with FOLFIRI in patients with BRAF V600E-mutated colorectal cancer. The results showed promising antitumour activity and tolerable toxicity with this combination therapy.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton, Wenfeng Chen, Regina Esser, Johannes Nippgen, Howard Burris
Summary: The study investigated the efficacy of cetuximab plus irinotecan in RAS-wild-type metastatic colorectal cancer patients as second-line treatment, showing improvements in progression-free survival, objective response rate, and quality of life. Additionally, almost half of patients in the irinotecan arm received poststudy cetuximab therapy.
Article
Oncology
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng
Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.
Article
Oncology
Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Joern Ruessel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Goehler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Carsten Bokemeyer, Joerg Steighardt, Franziska Cygon, Stefan Ibach, Alexander Stein, Joseph Tintelnot
Summary: The study confirms the effectiveness and tolerability of FOLFOXIRI plus bevacizumab as a first-line treatment for mCRC, but challenges remain in its clinical implementation.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Pui Lam Yip, Wai Him Brian Fung, Francis Ann Shing Lee, Chak Fei Lee, Natalie Sean Man Wong, Shing Fung Lee
Summary: This retrospective study reports the real-world effectiveness and safety of modified CAPIRI-P (mCAPIRI-P) regimen in patients with metastatic colorectal cancer. The results show that mCAPIRI-P is a safe and effective first-line treatment for RAS wild-type advanced colorectal cancer, and further research is warranted.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ming Quan, Jingde Chen, Zhiqin Chen, Yannan Hai, Ying Zhou, Qian Chao, Chen Chen, Huajun Li, Mei Wang, Yong Gao
Summary: In patients with RAS wild-type metastatic colorectal cancer (mCRC) previously treated with anti-EGFR therapy, cetuximab in combination with camrelizumab and liposomal irinotecan showed promising antitumor activity and well-tolerated toxicity.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Alexey V. Sorokin, Preeti Kanikarla Marie, Lea Bitner, Muddassir Syed, Melanie Woods, Ganiraju Manyam, Lawrence N. Kwong, Benny Johnson, Van K. Morris, Philip Jones, David G. Menter, Michael S. Lee, Scott Kopetz
Summary: This study evaluates the therapeutic efficacy and safety of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer using patient-derived xenografts and clinical trials, identifies biomarkers of response, and uncovers targetable mechanisms of resistance.
Article
Oncology
E. Van Cutsem, I Danielewicz, M. P. Saunders, P. Pfeiffer, G. Argiles, C. Borg, R. Glynne-Jones, C. J. A. Punt, A. J. Van de Wouw, M. Fedyanin, D. Stroyakovskiy, H. Kroening, P. Garcia-Alfonso, H. Wasan, A. Falcone, R. Fougeray, A. Egorov, N. Amellal, V Moiseyenko
Summary: The TASCO1 trial evaluated the use of trifluridine/tipiracil plus bevacizumab (TT-B) in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy, and the results showed that TT-B has potential therapeutic benefits.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Sri Harsha Tella, Nathan Foster, Shi Qian, Tran Nguyen, Mitesh J. Borad, Robert R. McWilliams, Steven R. Alberts, Wen Wee Ma, Sakti Chakrabarti, Briant Fruth, Jaclynn Wessling, Mindy Hartgers, Leslie Washburn, Martin E. Fernandez-Zapico, Tara L. Hogenson, Henry Pitot, Zhaohui Jin, Amit Mahipal
Summary: This study investigated the safety and efficacy of trifluridine/tipiracil in combination with irinotecan for refractory, advanced unresectable biliary tract carcinoma. The combination treatment showed promising results in terms of progression-free and overall survival. Adverse events were observed, but the genetic mutation status did not affect treatment response. Larger randomized trials are needed to confirm these findings.
Review
Oncology
Yun-Wang Chen, Min Yang, Ming-Xing Wang, Jia-Hong Jiang, Ding-Yi Jiang, Zhe-Ling Chen, Liu Yang
Summary: This article reports two cases of refractory hypokalemia caused by cetuximab without hypomagnesemia. The occurrence of hypokalemia was clearly correlated with the cetuximab, and they were significantly improved after stopping or reducing the dose. At the same time, the appearance of hypokalemia is significantly related to the efficacy of cetuximab.
Article
Oncology
Yujiro Nishizawa, Naotsugu Haraguchi, Hirotoshi Kim, Yoshihito Ide, Ken Nakata, Shu Okamura, Toshihiro Kudo, Taroh Satoh, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi
Summary: This study compared the efficacy and safety of SOX+B-mab and SOX+C-mab in patients with wild-type KRAS recurrent advanced CRC. The results showed that there was almost no difference in first-line chemotherapy between the two regimens, but the OS and PFS were significantly better in the SOX+C-mab group when early tumor shrinkage was >=20.
Article
Biochemistry & Molecular Biology
Alessandra Fraternale, Marta De Angelis, Riccardo De Santis, Donatella Amatore, Sofia Masini, Francesca Monittola, Michele Menotta, Federica Biancucci, Francesca Bartoccini, Michele Retini, Valentina Fiori, Raoul Fioravanti, Fabio Magurano, Laura Chiarantini, Florigio Lista, Giovanni Piersanti, Anna T. Palamara, Lucia Nencioni, Mauro Magnani, Rita Crinelli
Summary: The life cycle of SARS-CoV-2 is influenced by the environmental redox state, with a reducing environment impairing spike protein binding to ACE2 and an oxidizing environment promoting their interaction. Synthetic low molecular weight thiols induce a more reduced state in the receptor binding domain of the spike protein, impairing ACE2 binding and interfering with protein folding and viral replication. These thiols could potentially serve as innovative anti-SARS-CoV-2 therapeutics.
Review
Pharmacology & Pharmacy
Sara Biagiotti, Faiza Abbas, Mariele Montanari, Chiara Barattini, Luigia Rossi, Mauro Magnani, Stefano Papa, Barbara Canonico
Summary: This article provides an overview of extracellular vesicles (EVs) nature, features, methodologies for isolation/preparation, and characterization/visualization. EVs have extensive applications in nanomedical-drug delivery and regenerative medicine, offering advantages over synthetic vehicles or nanoparticles. The article particularly focuses on red blood cell-derived extracellular vesicles (RBCEVs), discussing their biogenesis, isolation/production methods, and therapeutic applications. RBCEVs show promise as a versatile platform for clinical applications and pharmaceutical exploitations.
Review
Oncology
Daniele Rossini, Alessandra Boccaccino, Martina Carullo, Carlotta Antoniotti, Giovanni Dima, Paolo Ciraci, Federica Marmorino, Roberto Moretto, Gianluca Masi, Chiara Cremolini
Summary: This study examined the predictive impact of primary tumor side on the efficacy of anti-EGFR agents in the first-line therapy of RAS wt mCRC. The results showed that the use of anti-EGFR agents was associated with higher overall response rate and longer overall survival in left-sided mCRC patients, while the use of bevacizumab was associated with better progression-free survival in right-sided mCRC patients. Therefore, the choice of upfront therapy for RAS wt mCRC patients should be based on the primary tumor location, with anti-EGFRs recommended for left-sided tumors and bevacizumab preferred for right-sided tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Rossella Cannarella, Carmelo Gusmano, Rosita A. Condorelli, Andrea Bernini, Jurgen Kaftalli, Paolo Enrico Maltese, Stefano Paolacci, Astrit Dautaj, Giuseppe Marceddu, Matteo Bertelli, Sandro La Vignera, Aldo E. Calogero
Summary: This study investigated five unrelated patients with cHH/KS and identified a new pathogenic variant in the CHD7 gene and three new variants of unknown significance in the IL17RD, FGF17, and DUSP6 genes. Further functional studies are needed to confirm their association with cHH.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Virology
Chiara Orlandi, Giuseppe Stefanetti, Simone Barocci, Gloria Buffi, Aurora Diotallevi, Ettore Rocchi, Marcello Ceccarelli, Sara Peluso, Daniela Vandini, Eugenio Carlotti, Mauro Magnani, Luca Galluzzi, Anna Casabianca
Summary: The humoral response after vaccination was compared in individuals who received different COVID-19 vaccine schedules. Heterologous vaccination induced a stronger immune response than the two homologous vaccinations. The ChAd/BNT vaccine schedule exhibited the longest time of anti-S IgG negativization and slow decay of the titer over time. Factors such as vaccine schedule and BMI had a significant impact on the immune response.
Article
Multidisciplinary Sciences
Keyue Sun, Daniela Bochicchio, Pierre-Alain Clavien, Philipp Dutkowski, Bostjan Humar
Summary: Uterine transplantation is a new approach for treating absolute uterine factor infertility, which has shown success in animal models and led to pregnancy in clinical practice. Continuous optimization of the procedure is still needed.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2023)
Article
Oncology
Piero Boraschi, Roberto Moretto, Francescamaria Donati, Beatrice Borelli, Giuseppe Mercogliano, Luigi Giugliano, Alessandra Boccaccino, Maria Clotilde Della Pina, Piero Colombatto, Stefano Signori, Gianluca Masi, Chiara Cremolini, Lucio Urbani
Summary: This study aimed to evaluate the clinical outcome of disappearing liver metastases (DLM) and small residual lesions in metastatic colorectal cancer patients treated with first-line chemotherapy using hepatobiliary contrast-enhanced and diffusion-weighted MR imaging (DW-MRI). The results showed that DLM assessed via hepatobiliary contrast-enhanced and DW-MRI very probably indicate a complete response in patients without chemotherapy-induced sinusoidal obstruction syndrome. For these patients, a follow-up with liver MRI can be considered, and resection should be performed in the case of disease relapse. The surgical removal of small remnants of liver metastases should always be advocated whenever technically possible.
Editorial Material
Oncology
Gianluca Masi
Article
Oncology
Maurizio Muscaritoli, Alessandra Modena, Matteo Valerio, Paolo Marchetti, Roberto Magarotto, Silvia Quadrini, Filomena Narducci, Giuseppe Tonini, Teresa Grassani, Luigi Cavanna, Camilla Di Nunzio, Chiara Citterio, Marcella Occelli, Antonia Strippoli, Bruno Chiurazzi, Antonio Frassoldati, Giuseppe Altavilla, Antonio Lucenti, Fabrizio Nicolis, Stefania Gori
Summary: Malnutrition and cachexia in cancer patients have a negative impact on treatment, outcomes, quality of life, and survival. However, the risk of malnutrition and cachexia is still overlooked in cancer patients. A study revealed that 51% of patients already had nutritional deficiencies at their first oncology visit. These findings emphasize the importance of proactive, early management of malnutrition in cancer patients.
Article
Infectious Diseases
Marilena Agosta, Daniela Bencardino, Marta Argentieri, Laura Pansani, Annamaria Sisto, Marta Luisa Ciofi Degli Atti, Carmen D'Amore, Pietro Bagolan, Barbara Daniela Iacobelli, Mauro Magnani, Massimiliano Raponi, Carlo Federico Perno, Francesca Andreoni, Paola Bernaschi
Summary: A rapid and unexpected spread of NDM-1 carbapenemase-producing Klebsiella pneumoniae and Escherichia coli cases were reported in a neonatal surgical unit in Rome, Italy. A total of 20 strains (8 K. pneumoniae and 12 E. coli) with NDM-1 gene were isolated from 17 out of 230 stool samples collected from neonates admitted in the ward. Infection control interventions prevented the dissemination of the strains in the ward.
Article
Biochemistry & Molecular Biology
Federica De Castro, Erika Stefano, Francesco Paolo Fanizzi, Riccardo Di Corato, Pasant Abdalla, Francesca Luchetti, Maria Gemma Nasoni, Rosaria Rinaldi, Mauro Magnani, Michele Benedetti, Antonella Antonelli
Summary: This study evaluated the feasibility of loading platinum-based nucleoside derivatives into human red blood cells and found that these complexes are stable and suitable for incorporation. This opens up new possibilities for incorporating other metalated nucleobase analogues with potential antitumor and/or antiviral activity into red blood cells.
Article
Genetics & Heredity
Francesca Cristofoli, Muharrem Daja, Paolo Enrico Maltese, Giulia Guerri, Benedetta Tanzi, Roberta Miotto, Gabriele Bonetti, Jan Miertus, Pietro Chiurazzi, Liborio Stuppia, Valentina Gatta, Stefano Cecchin, Matteo Bertelli, Giuseppe Marceddu
Summary: We have developed MAGI-ACMG, a classification algorithm that allows the classification of sequencing variants according to the recommendations of ACMG and ACGS. This algorithm utilizes the VarSome API, integrates the AutoPVS1 tool for precise evaluation, and performs customized assignment of criteria. Additionally, we propose a sub-classification scheme for variants of uncertain significance and introduce a pathogenicity potential criterion for upgrading clinical significance.
Article
Oncology
Valentina Fanotto, Daniele Rossini, Mariaelena Casagrande, Francesca Bergamo, Andrea Spagnoletti, Daniele Santini, Carlotta Antoniotti, Samanta Cupini, Francesca Daniel, Vincenzo Nasca, Guglielmo Vetere, Alberto Zaniboni, Beatrice Borelli, Martina Carullo, Veronica Conca, Alessandro Passardi, Emiliano Tamburini, Gianluca Masi, Nicoletta Pella, Chiara Cremolini
Summary: The decision to resect the primary tumor in asymptomatic patients with synchronous metastatic colorectal cancer (mCRC) has been studied. This study found that primary tumor resection is associated with improved survival and lower incidence of serious gastrointestinal and surgical adverse events. The efficacy and toxicity profile of FOLFOXIRI plus bevacizumab is independent of primary tumor resection.
Article
Oncology
Giacomo Aringhieri, Gianfranco Di Salle, Silvia Catanese, Caterina Vivaldi, Francesca Salani, Saverio Vitali, Miriam Caccese, Enrico Vasile, Virginia Genovesi, Lorenzo Fornaro, Rachele Tintori, Francesco Balducci, Carla Cappelli, Dania Cioni, Gianluca Masi, Emanuele Neri
Summary: This study evaluated the impact of abdominal visceral and subcutaneous fat volumes, psoas muscle volume, and the visceral-to-subcutaneous volume ratio on overall survival and progression-free survival in patients with advanced gastric cancer. The results showed that patients with a higher visceral-to-subcutaneous volume ratio had poorer survival outcomes and a less favorable response to chemotherapy.